http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-102171141-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23L33-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-04 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A23L33-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-04 |
| filingDate | 2018-05-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2020-10-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2020-10-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-102171141-B1 |
| titleOfInvention | Composition for preventing, treating, or improving obesity comprising the peptides derived from LGI3 as the active ingredients |
| abstract | The present invention relates to a composition for preventing, treating, or improving obesity comprising a peptide derived from adipocaine LGI3 as an active ingredient, wherein the P25 to P28 peptide derived from LGI3 has an adipocyte differentiation inhibitory activity like LGI3, P32 to P34 peptides function to block the adipocyte differentiation inhibitory activity of LGI3. The composition comprising the LGI3-derived peptide of the present invention as an active ingredient promotes the reduction of visceral fat, which is an important cause of obesity and obesity-related metabolic abnormalities, improves blood leptin and lipid composition, and reduces liver triglycerides. By improving liver function, it is possible to prevent, treat, or improve various obesity-related metabolic abnormalities caused by a high fat diet. In addition, the composition of the present invention induces the regulation of adipocyte differentiation and the control of adipose tissue inflammation, and has the advantage of having little or no side effects exhibited when the existing obesity treatments act on the central nervous system or digestive system. Accordingly, the LGI3-derived peptide of the present invention and materials that can be developed by using it as a leading material are used in various fields, such as pharmaceutical, external, food additive, and cosmetic material composition for preventing and treating obesity and related metabolic abnormalities. It is expected to be possible. |
| priorityDate | 2018-05-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 717.